Intravitreal Bevacizumab in the Treatment of Diabetic Ocular Neovascularization

Ababneh, Osama H.; Yousef, Yacoub A.; Gharaibeh, Almutez; Ameerh, Mohammed A. Abu; Abu-Yaghi, Nakhleh; Bdour, Muawyah

doi:10.1097/iae.0b013e3182721153

Cited by 13 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These effects were maintained for 3 months in all eyes and tended to be stable at 9 months with no side effects from the injections 18 . In the series reported by Ababneh et al ., more than 50% of the new vessels were stable or improved at 6 months 6 . Arevalo et al .…”

Section: Discussionmentioning

confidence: 89%

Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections

Zhang

Zhou

et al. 2018

Sci Rep

View full text Add to dashboard Cite

This study reports the short-term efficacy and safety of intravitreal conbercept injections for neovascularization at the disc (NVD) in patients with proliferative diabetic retinopathy (PDR). Conbercept is a recombinant fusion protein with a high affinity for all isoforms of vascular endothelial growth factor (VEGF)-A, placental growth factor and VEGF-B. A prospective case series study was conducted in 15 patients (15 eyes). Patients had complete ocular examinations and received a 0.5 mg intravitreal conbercept injection followed by supplemental pan-retinal photocoagulation (PRP). Optical coherence tomography angiography (OCTA) was performed before and after treatment. Before treatment, the mean NVD area was 1.05 ± 0.33 mm2, and it decreased to 0.56 ± 0.17 mm2 after an interval of 7.5 d (p = 0.000). One eye required vitrectomy during follow-up. Recurrent NVD was observed in 2 eyes, which resolved after repeated injections. The remaining 12 eyes were stable over a mean follow-up period of 8.3 months. The mean area of the NVD in 14 patients without vitrectomy was 0.22 ± 0.11 mm2 (p = 0.000) at the last visit. Intravitreal conbercept injections combined with intensive PRP are an effective and safe treatment for PDR with NVD. Quantitative information on NVD can be obtained with OCTA, which may be clinically useful in evaluating the therapeutic effect.

show abstract

Section: Discussionmentioning

confidence: 89%

Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections

Zhang

Zhou

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In addition, the contraction of the deep capillaries of the iris and the shielding effect of the iris pigment on the small deep blood vessels reduces the number of blood vessels on OCT images [16]. Moreover, Ababneh et al [17] found that intravitreal anti-VEGF treatment caused regression of iris neovascularization in DM. They also observed that the response of the new vessels of the iris was greater than that of the newer vessels of the optic disc and those elsewhere.…”

Section: Discussionmentioning

confidence: 99%

Changes in the Iris and retinal vessel on optical coherence tomography angiography after intravitreal anti-vascular endothelial growth factor in diabetic macular edema

Zou,

Jia,

Xue

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives Analyze quantitative changes of iris and retinal vessels in diabetic macular edema (DME) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) and evaluate their correlations. Methods This was a case-cohort study. A total of 26 eyes of DME patients received anti-VEGF treatments and were reviewed three times of follow-up. Images of iris and retinal vessels were obtained before and after treatment and the area density of the vessel (VAD) and the density of the vessel skeleton (VSD) were quantitatively analyzed. Results There was no significant change in the iris VAD after the third injection (p > 0.05), but the VSD of iris decreased (p ＜0.05). Further linear regression analysis showed that the difference between postoperative and pretreatment iris VSD was negatively correlated with baseline(R = 0.793, B = -1.242, p = 0.000), but not with age, sex, and baseline visual acuity (all p > 0.05). Conclusions Iris vessels are more sensitive to anti-VEGF than retinal vessels.

show abstract

“…The Diabetic Retinopathy Clinical Research (DRCR) phase 2 and bevacizumab or laser therapy (BOLT) study showed favorable results with use of bevacizumab along with laser therapy rather than laser therapy alone. [ 25 26 27 ]…”

Section: Egf a Ctions And I mentioning

confidence: 99%

Advances in diabetic retinopathy

Agarwal¹,

Jindal

Vk³

et al. 2014

Indian J Endocr Metab

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is a complication of long-term diabetes mellitus (DM). Over the last 2 decades lot of work has been on early diagnosis of DR and screening programs have been designed to help the masses. Large numbers of clinical studies have been done for patients of diabetes and DR wherein the role of blood sugar control, metabolic control, role of oral medicines for DR, role of imaging, fluorescein angiography, and retinal photocoagulation has been studied. Newer treatment modalities are being devised and studied for better patient care. We discuss these issues in our review highlight and newer advances over the last few years.

show abstract

Intravitreal Bevacizumab in the Treatment of Diabetic Ocular Neovascularization

Abstract: Intravitreal bevacizumab is a well-tolerated medication that causes regression of abnormal diabetic neovascularization. New vessels of the iris responded more than new vessels of the optic disk and new vessels elsewhere.

Cited by 13 publications

References 38 publications

Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections

Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections

Changes in the Iris and retinal vessel on optical coherence tomography angiography after intravitreal anti-vascular endothelial growth factor in diabetic macular edema

Advances in diabetic retinopathy

Contact Info

Product

Resources

About